161 related articles for article (PubMed ID: 16732715)
1. Therapeutic potential of angiotensin receptor blockers in hypertension.
Cheung BM
Expert Opin Investig Drugs; 2006 Jun; 15(6):625-35. PubMed ID: 16732715
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
4. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
5. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
Mistry NB; Westheim AS; Kjeldsen SE
Expert Opin Pharmacother; 2006 Apr; 7(5):575-81. PubMed ID: 16553573
[TBL] [Abstract][Full Text] [Related]
7. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Martin J; Krum H
Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
[TBL] [Abstract][Full Text] [Related]
8. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
9. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
[No Abstract] [Full Text] [Related]
10. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Elliott WJ
Curr Hypertens Rep; 2000 Aug; 2(4):402-11. PubMed ID: 10981176
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Chrysant SG; Chrysant GS
J Clin Hypertens (Greenwich); 2004 Aug; 6(8):445-51. PubMed ID: 15308883
[TBL] [Abstract][Full Text] [Related]
13. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
14. [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Sidorenko BA; Preobrazhenskiĭ DV; Stetsenko TM; Tarykina EV; Tsurko VV
Kardiologiia; 2003; 43(2):88-95. PubMed ID: 12891278
[TBL] [Abstract][Full Text] [Related]
15. Valsartan in the treatment of heart attack survivors.
Jugdutt BI
Vasc Health Risk Manag; 2006; 2(2):125-38. PubMed ID: 17319456
[TBL] [Abstract][Full Text] [Related]
16. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
[TBL] [Abstract][Full Text] [Related]
17. [Application of AT1-angiotensin II receptor blocker valsartan in clinical practice].
Maksimov ML; Mochkin IA; Starodubtsev AK
Kardiologiia; 2011; 51(8):77-84. PubMed ID: 21942964
[No Abstract] [Full Text] [Related]
18. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
19. VALIDD should not invalidate angiotensin-receptor blockers.
Ahmed A; Perry GJ; Husain A
Lancet; 2007 Jun; 369(9579):2053-4. PubMed ID: 17586284
[No Abstract] [Full Text] [Related]
20. Valsartan after myocardial infarction.
Güleç S
Anadolu Kardiyol Derg; 2014 Dec; 14 Suppl 2():S9-13. PubMed ID: 25604205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
